Author

Nikhil Ramavenkat

National Institute of Neurological Disorders and Stroke

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Genetic & Genomic Medicine· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 3 Organism:human· 3 Research Focus:differential expression· 2 Approach:statistical model· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Assay:ChIP-seq· 1 Approach:deep learning· 1

Frequent Co-Authors

David T. AsuzuiD· 2 shared Debjani MandaliD· 2 shared Dhruval Bhatt· 2 shared Dustin MullaneyiD· 2 shared Kenneth AldapeiD· 2 shared Prashant ChittiboinaiD· 2 shared Sheelu VargheseiD· 2 shared Zied AbdullaeviD· 2 shared

Activity by Year

2024-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 44 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

David T. AsuzuORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Variable Schwann cell merlin inactivation is targetable with TEAD1 inhibition in schwannomas.

Maxwell Thomas Laws, Dhruval Bhatt, Debjani Mandal, Nikhil Ramavenkat, David T. Asuzu, Stefan Stoica, Ihika Rampalli, Dustin Mullaney, Liyam Laraba, Hannah Odom, Niveditha Ravindra, Sheelu Varghese, Tracy Tzu-Ling Tang, Xiyuan Zhang, John Frederick Shern, , Prashant Chittiboina

The paper identifies variable merlin inactivation in schwannomas and shows TEAD1 inhibition can reverse hippo signaling and suppress tumor growth.

bioRxiv · Nov 15, 2025 · PreprintCancer Biology

Phosphoproteomic dysregulation drives tumor proliferation in Cushing's disease

David T. Asuzu, Dhruval Bhatt, Dustin Mullaney, Debjani Mandal, Diana Nwokoye, Sheelu Varghese, Daniela Tortoza Lopez, Nikhil Ramavenkat, Kory Johnson, Abdel Elkahloun, Zied Abdullaev, Kenneth Aldape, Dragan Maric, Clarisse Quignon, N MALIK, , Prashant Chittiboina

This study identifies phosphoproteomic dysregulation as a driver of tumor proliferation in Cushing's disease and demonstrates reversibility using an FDA-approved PP2A agonist.

bioRxiv · Sep 28, 2025 · PreprintCancer Biology

A dynamic microRNA profile that tracks a chemotherapy resistance phenotype in osteosarcoma. Implications for novel therapeutics.

Christopher E. Lietz, Erik T. Newman, Andrew D. Kelly, David Haosen Xiang, Ziying Zhang, Nikhil Ramavenkat, Joshua J. Bowers, Santiago A. Lozano‐Calderón, David H. Ebb, Kevin A. Raskin, Gregory Michael Cote, Edwin Choy, G. Petur Nielsen, Ioannis S. Vlachos, Benjamin Haibe‐Kains, Dimitrios Spentzos

The paper identifies a dynamic microRNA profile associated with chemotherapy resistance in osteosarcoma and predicts novel therapeutic targets that could reverse resistance.

medRxiv · Jun 19, 2024 · PreprintGenetic & Genomic Medicine